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Abstract
Moore, Courtney Elyse. M.S., Department of Neuroscience, Cell Biology & Physiology,
Wright State University, 2017. Upstream regulators of VRAC activation in Human
1321N1 Astrocytoma Cells

Cells rely on a constant volume not only for structural stability but also for normal
homeostatic processes to occur. In the brain and CNS, cells can regain their normal
volume through a process termed regulatory volume decrease (RVD). A key component
of a cells’ response to cell swelling is the activation of channel(s) responsible for the
efflux of chloride current, ICl,swell. Volume regulated anion channels (VRAC) which
mediate ICl,swell have been implicated in controlling cell volume during RVD, but the
mechanisms which activate this channel are not completely understood. In this study, I
examined the role of G protein-coupled signaling via P2Y2 purinergic receptors for
activation of VRAC in osmotically swollen human astrocytoma cells. Whole cell patch
clamp recordings were performed on 1321N1 cells stably transfected to express the
human P2Y2 receptor. This tumor cell does not show VRAC activation in the native cell
type; however, VRAC activation is displayed in the transfected 1321N1 cells. Cells were
sequentially perfused with isoosmotic (290 mOsm) and hypoosmotic (200 mOsm and
250 mOsm) solutions containing 100 mM CsCl as the major electrolyte. The same CsCl
concentration was used in the isoosmotic patch electrode solution. Voltage clamp
recordings lasting 100 msec were made in 20 mV steps between -100 mV and +120 mV
iii

every 30 sec. For some experiments, inhibitors and activators of GPCRs, purinergic
signaling, and ATP release pathways were added to the perfusate solutions. In others,
pertussis toxin was added to the patch electrode solution. Hypoosmotic exposure evoked
an outwardly rectifying current which inactivated over time at the higher membrane
voltages and was inhibited by DCPIB; characteristics ascribed to VRAC. A smaller
VRAC current was observed when cells were perfused with a 250 mOsm hypoosmotic
CsCl solution. VRAC was not activated in isoosmotic solutions but the VRAC response
in hypoosmotic solutions was enhanced in the presence of thrombin. VRAC activation
was completely blocked by adding suramin to the hypoosmotic solution or pertussis toxin
to the patch electrode solution, both of which are inhibitors of G-protein signaling
pathways. Carbenoxolone, which can block ATP release from swollen cells and can
directly inhibit VRAC also blocked VRAC activation. Adding ATP did not rescue cells
from this inhibition; however, adding thrombin to activate a separate G-protein coupled
signaling pathway did result in a partial recovery. In contrast, meclofenamate, another
ATP efflux inhibitor had no effect on the VRAC response to hypoosmotic exposure. I
conclude GPCRs are necessary for VRAC activation in these human astrocytoma cells.
Exogenous thrombin increased an osmotically-sensitive current but, like exogenous ATP,
had no effect on VRAC activation during isoosmotic exposure. If endogenously released
ATP is responsible for VRAC activation via the P2Y2 receptor, it is not effluxed via gap
junction hemi-channels. Future studies are needed to measure ATP release during
hypoosmotic exposure and identify the specific GPCR that mediates VRAC activation.
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I. Background and Literature Review
A. Cell Volume Regulation
Introduction
Cells rely on a constant volume not only for structural stability but also for normal
homeostatic processes to occur including cell proliferation, apoptosis, and migration
(Okada, Sato & Numata 2009). Most mammalian cells are bathed in extracellular fluid at
a constant osmolarity however injury or stress can lead to changes in the extracellular
osmolarity and cell volume alterations. These alterations in cell volume may be limited
by extracellular tissue constraints. For example, brain volume is limited by the size of the
cranium. Considering this limitation of brain tissue, the ability of cells to regulate their
volume through osmolyte movement via uptake, release, and/or breakdown, is critical for
cell survival (Lang et al. 1998).
Two major types of cells are in the brain parenchyma: neurons and glial cells. Neurons,
the basic functional unit of the nervous system, are electrically excitable cells with
specialized

structures

and

biochemistry for

conducting

nerve

impulses

and

communicating with other cells in the central nervous system (Purves et al. 2001).
Astrocytes are a type of glial cells and are the largest and most numerous cells in the gray
matter of brain and spinal cord. These cells regulate the extracellular ionic and chemical
environment and have been implicated in modifying neuronal signaling (Chung, Allen &
Eroglu 2015). In the 1960s, astrocytes were considered to do little more than occupy
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space in the CNS (Van Herreveld, Crowell & Malhorta 1965). However since then,
scientists have found that astrocytes play an important role in brain function by acting not
only through extracellular buffering of neurotransmitters but also through cellular
signaling and volume regulation. Depending on location in the brain, astrocytes occupy
approximately 20-30% of the brain volume (Nedergaard, Ransom & Goldman 2003) and
are well known for regulating the extracellular space around neurons (Chung, Allen &
Eroglu 2015). Astrocytes have also been shown to protect neurons and increase the
neuron cell survival rate in many pathological settings (Chen & Swanson 2003).
Manipulating astrocyte function is thus an important strategy to enhance neuronal
survival and improve the outcome following brain injury.

Regulating cell volume
Cell volume is regulated through various mechanisms at all times. In addition to volume
regulatory mechanisms that are active during osmotic stress, cells also regulate volume
under homeostatic conditions. Because there is a constant passive flow of ions and
metabolites into and out of cells, cell volume control mechanisms are active for
homeostasis or steady-state conditions. Flow of solutes and water across a cell’s semipermeable plasma membrane is driven by electrochemical gradients and osmotic
pressure, respectively. In an ideal semi-permeable membrane at equilibrium, solute
concentrations would be equalized across the divide; however in mammalian cells, an
electrochemical gradient is present for most inorganic ions and organic osmolytes. The
cell maintains a constant cell volume by active and passive solute transport across the cell
membrane. Under steady-state conditions, this passive osmolyte flow into and out of the
2

cell consists mainly of potassium, sodium, and chloride ions. To balance this passive flow
of osmolytes driven by their electrochemical gradient, mammalian cells possess a
sodium-potassium enzyme (Na+/K+-ATPase) found on the plasma membrane which
pumps positively-charged sodium ions out of the cell and positively-charged potassium
ions into the cell against their concentration gradients.
During cell shrinkage (i.e. hypertonic stress), many cells respond with active uptake of
organic osmolytes and inorganic ions through various mechanisms. This uptake is
coupled to an influx of water and is termed regulatory volume increase (RVI). RVI
uptake mechanisms include the exchange of hydrogen and sodium ions via the Na-/H+
antiporter, the exchange of chloride and bicarbonate through the Cl-/HCO3- antiporter,
the uptake of sodium, potassium and chloride ions through the NKCC symporter, and the
uptake of sodium chloride through the Na+/Cl- symporter (Mongin & Orlov 2001). Initial
RVI responses to acute cell shrinkage results in the net accumulation of inorganic ions
such as sodium, potassium, bicarbonate, and chloride. But, the solutes accumulating
during prolonged cell shrinkage also consist of organic osmolytes such as sorbitol,
taurine, and betaine (Hoffman, Lambert & Pedersen 2009, Wehner et al. 2003).
In contrast, after acute swelling, cells undergo regulatory volume decrease (RVD) by
releasing ions and organic osmolytes. RVD involves the release of inorganic ions and
organic osmolytes (Lang et al. 1998). This efflux is accomplished mainly through
potassium and chloride channels or transporters but it is also achieved through the
extrusion of amino acids such as taurine and polyols (Pasantes-Morales, Murray,
Sanchez-Olea & Morán 1994, Pasantes-Morales et al. 2000, Ordaz et al. 2004).
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B. Chloride Channels
Chloride is the most abundant anion in most mammalian cells under physiological
conditions. Chloride movement into and out of cells occurs through various active and
passive transport pathways. The energetic cost for chloride ion movement is relatively
low in most mammalian cells as the equilibrium potential for chloride is close to the
normal plasma membrane resting potential. The normal reversal potential for chloride in
neurons is approximately -60 mV (Purves et al. 2001). However, astrocytes are high
chloride cells. Cultured rat astrocytes demonstrate internal chloride concentrations
between 20 and 40 mM (Kettenmann, Backus & Schachner 1987). As a result, rat
astrocytes display an equilibrium potential for chloride of -31 mV (Lascola & Kraig
1996). In addition, chloride movement also occurs when a positively-charged cation, such
as potassium, is effluxed. Thus the net movement of these ions is electrically neutral.
Passive chloride efflux requires that the equilibrium potential for Cl- is more positive than
the cell’s membrane potential. During homeostatic, or steady-state, conditions, chloride
movement is achieved through transporters such as the Na+/Cl- cotransporter,
Na+/K+/2Cl- cotransporter (NKCC), Cl-/HCO3- anion exchanger, and the K+/Clcotransporter or through various anion channels including Ca2+-activated Cl- channels
(CaCC), cAMP/PKA-activated cystic fibrosis transmembrane conductor regulator
(CFTR), members of the chloride channel family (ClC-X), and volume-regulated anion
channels (VRAC) (Hoffman, Lambert & Pedersen 2009). In cells with a small
electrochemical gradient of chloride, chloride movement is minimal during steady-state
conditions. With active transport, such as during RVI, there is secondarily active uptake
4

of chloride that occurs via the NaCl symporter and the NKCC symporter (Hoffman,
Lambert & Pedersen 2009, Wehner et al. 2003). In contrast, chloride is passively and
actively transported to the extracellular fluid during RVD through VRAC, ClC-X, and the
K+/Cl- cotransporter (Hoffman, Lambert & Pedersen 2009). Chloride movement has been
extensively studied in transepithelial transport in the kidney (Lang et al. 1990, Lang &
Paulmichl 1995, Furst et al. 2000, Helix, Strobaek, Dahl & Christophersen 2003) as well
as the intestine and endothelial cells (Kubo & Okada 1992, Nilius, Eggermont &
Droogmans 2000, Lim et al. 2006); however less information is known about chloride
movement in neurons and glial cells in the CNS.

Chloride channels implicated in volume regulation
Because chloride is the most abundant anion in cells, chloride can be effective as an
osmolyte controlling water movement and cell volume. In astrocytes, organic osmolytes
and Cl- fluxes contribute to cell volume regulation in response to acute and chronic
osmotic challenges (Mongin & Kimelberg 2002). Chloride is released from cells during
acute cell swelling through channels and transporters on the plasma membrane. It has
been estimated that 60-70% of chloride efflux following acute cell swelling occurs
through channels in cultured astrocytes and human glioma cells (Ernest, Weaver, Van
Duyn & Sontheimer 2005).

5

Electrophysiology of cells during RVD due to chloride conductance
Chloride current is minimal under steady state conditions; however, chloride conductance
has been found to increase during hypoosmotic swelling (Bakhramov, Fenech & Bolton
1995) but not in hypertonically shrunken cells (Estevez, Bond & Strange 2001). The
chloride current activated during swelling, ICl,swell, is ubiquitously present in mammalian
cells (Duan et al. 1997, Jentsch 2016).
ICl,swell, had long been characterized by its electrophysiological behavior; however the
identity of the specific molecule responsible for ICl,swell was unknown until more recently.
This current activates at positive potentials under hypoosmotic conditions and thus, is
outwardly rectifying. In HEK293 cells, ICl,swell is not dependent on changes in
intracellular calcium concentration (Weylandt et al. 2003). Two voltage-gated chloride
channels have been implicated in volume decrease following osmotic swelling, ClC-2
and ClC-3. ClC-2 channels generate an inwardly rectifying current and are inhibited by
chloride channel blockers and cadmium ions. ClC-3 is an outwardly rectifying channel
which is assumed to be constitutively open when present in the cell membrane. Until
recently, the ClC-3 channel protein had been proposed as the prominent protein that
encodes the channel responsible for ICl,swell, but more recent studies have suggested
otherwise (Duan et al. 1997, Weylandt et al. 2003, Syeda et al. 2016). VRAC is
characterized by an outwardly rectifying anion-selective current at depolarized potentials
(Blum, Walsh & Dubyak 2009). The current that is associated with VRAC develops
within the first few minutes following hypoosmotic challenge. Inactivation of this current
occurs at more positive potentials and the degree of this inactivation has been found to
vary between cell types (Nilius, Sehrer & Droogmans 1994). VRAC also is permeable to
6

some organic osmolytes (Mongin & Kimelberg 2002) such as taurine and glutamate and
this channel has been shown to be a major pathway for excitatory amino acid release
(Basarsky, Feighan & MacVicar 1999, Kimelberg & Mongin 1998, Phillis, Song &
O'Regan 1997).

Volume regulated anion channels
In the brain, volume regulated anion channels, VRACs, are widely expressed and have
been proposed to play an important role not only in cell proliferation, apoptosis, swellinginduced exocytosis and control of cell membrane potential (Okada et al. 2001, Nilius &
Droogmans 2003). These channels have also been shown to play an important role in
preventing detrimental cellular swelling, apoptosis and cell death during cerebral
ischemia (Mongin 2007, Adler 2014).
Research performed by Ernest and colleagues on cultured astrocytes and human glioma
cells found the inhibition of swelling-induced chloride channels and transporters also
inhibits RVD. These findings suggest that the volume increase is limited by quickly
activating volume-regulatory mechanisms (Ernest, Weaver, Van Duyn & Sontheimer
2005). Furthermore, volume-sensitive chloride current commonly associated with VRAC
can be activated independently of osmotic volume changes (Manolopoulos, Prenen,
Droogmans & Nilius 1997, Shimizu, Numata & Okada 2004). For example,
electrophysiological recordings using calf pulmonary artery endothelial cells found that
volume-sensitive chloride current may be activated by thrombin (Manolopoulos, Prenen,
Droogmans & Nilius 1997). Other patch clamp studies using human cervix HeLa cells
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have shown ICl,swell can be activated or enhanced independently of volume through the
application of GTPγS, TNFα, and ATP (Shimizu, Numata & Okada 2004).

Identification of LRRCs as components of VRAC
Although VRAC’s molecular identity is still not entirely understood, recent studies have
found that VRAC is formed by a heterooligomer of the leucine-rich-repeat-containing
proteins (LRRC) (Stauber 2015). One of these proteins, LRRC8, was originally
discovered and cataloged in 2003 and since then, there have been five isoforms of this
protein labeled: LRRC8A-E. LRRC8A was first studied in its mutated, dysfunctional
form which causes a rare type of agammaglobulinemia (Sawada et al. 2003). LRRC8A
knockout mice also exhibited a dramatic reduction in excitatory amino acid release when
exposed to hypoosmotic media (Hyzinski-Garcia, Rudkouskaya & Mongin 2014).
Further studies have found that T cell development and function were negatively affected
in LRRC8A knockout and these transgenic mice also demonstrated a modest block in B
cell development (Kumar et al. 2014). No experiments to identify VRAC have been
performed with the LRRC8A knockout mice in vivo; however, electrophysiological
recordings using LRRC8A knockdown HEK cells showed a strongly suppressed ICl,swell
under hypoosmotic conditions (Voss et al. 2014).
In HeLa cells, LRRC8A proteins form an oligomer of up to four subunits, termed
SWELL1, during osmotic challenges. The SWELL1 proteins then assemble to form
complexes. These complexes are sufficient to form anion channels sensitive to osmotic
stress (Syeda et al. 2016). Topology suggests the leucine-rich pore forming structure is
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imbedded inside the plasma membrane in comparison to previous studies suggesting
VRAC must be located on the outside of the plasma membrane to function properly
during RVD (Qiu et al. 2014). Qui and colleagues concluded that SWELL1 forms a porelike structure but it is unlikely that this protein functions on its own because overexpression of LRRC8A did not increase VRAC activity (Qiu et al. 2014). Channel gating
and pore formation of SWELL1 during swelling is still not entirely understood.

Drugs used to identify chloride channels activated in RVD
A variety of channel blockers have been used to study the role of VRAC for RVD. This
has permitted a characterization of the channel based on the selective ability of these
drugs to inhibit its conductance. Pharmacologically, VRAC conductance is blocked
partially or entirely by DIDS, SITS, NPPB, and DCPIB (Bowens, Dohare, Kuo &
Mongin 2012, Hoffman, Lambert & Pedersen 2009). In murine CNS cells, application of
DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid) in the extracellular fluid
inhibited volume-sensitive chloride current through VRAC (Harvey, Saul, Garner &
McDonald 2010). In other experiments using rat cerebral cortex slices, SITS and NPPB
were applied to the extracellular media. SITS (4-acetamido-4'-isothiocyanostrilbene-2,2'disulfonic acid) and NPPB (5-nitro-2-(3-phenyl-propylamino)benzoic acid) were found to
also inhibit RVD through VRAC (Phillis, Song & O'Regan 1997, Shen, Wu & Chou
1996). These inhibitors also block other chloride channels. However, research performed
by Decher and colleagues concluded that the ethacrynic acid derivative DCPIB (4-(2butyl-6,7-dichlor-2-cyclopentylindan-1-on-5-yl) oxobutyric acid) is a more selective
blocker of VRAC over other chloride channels (Decher et al. 2001). DCPIB inhibition is
9

reversible and not voltage dependent (Nilius & Droogmans 2003, Abdullaev et al. 2006).
DCPIB blocks swelling induced chloride current in vitro in calf bovine pulmonary artery
endothelial cells, guinea-pig atrial cardiomyocytes and Xenopus oocytes (Decher et al.
2001). In cultured astrocytes and human glioma cells, DCPIB treatment inhibited RVD
and excitatory amino acid release (Ernest, Weaver, Van Duyn & Sontheimer 2005,
Abdullaev et al. 2006). In vivo, pre-application of DCPIB has been shown to reduce
neonatal brain injury and improve behavior outcomes within 24 hours of treatments in
mouse pups following hypoxic induced conditions (Alibrahim et al. 2013). Despite the
anion channel specificity for VRAC, DCPIB may have other effects on other ion
channels such as activation of TREK potassium conductance in cultured astrocytes
(Minieri et al. 2013).
While VRAC has been characterized structurally, electrophysiologically, and
pharmacologically, the channel activation, pore formation, and channel gating are still not
understood. Many pathways have been suggested to activate and/or enhance the current
associated with VRAC during RVD, as discussed below.

C. ATP
Adenosine 5’-triphosphate (ATP) is widely known as a high energy intermediate in
metabolism but is also an important extracellular and intracellular signaling molecule in
the CNS. Osmotic cell swelling has been shown to release ATP from many cell types
(van der Wijk et al. 2003, Espelt et al. 2013) and in cultured astrocytes, ATP released
during hypoosmotic swelling acts on purinergic P2 receptors to stimulate ICl,swell (Darby
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et al. 2003) and excitatory amino acid release (Mongin & Kimelberg 2002). ATP can be
released through conductive channels including connexin hemi-channels and pannexin
channels or by exocytotic vesicular transport (Islam et al. 2012, Lohman & Isakson
2014). While the connexin- and pannexin-related release of ATP is still not entirely
understood, these channel-mediated pathways of ATP release are typically driven by a
steep electrochemical gradient (Espelt et al. 2013). The released extracellular ATP
concentration adjacent to the plasma membrane can reach or exceed 10 µM and at this
concentration ATP can stimulate purinergic signaling via P2Y receptors on the cell
surface (Dubyak & el-Moatassim 1993). In primary rat astrocytes, application of
hypoosmotic medium together with exogenous extracellular ATP resulted in a synergistic
increase of excitatory amino acid release suggesting ATP regulates VRAC (Mongin &
Kimelberg 2002). With this information, I plan to investigate the role purinergic signaling
plays in VRAC activation.

P2Y and P2X purinergic receptors
Purinergic signaling has been implicated in many physiological and pathological
conditions and processes including regulation of blood pressure and respiratory control,
neurotransmission, inflammation, and cancer (Lohman & Isakson 2014). Purinergic
receptors consist of three main classes: metabotropic P1 adenosine receptors (ARs),
ionotropic P2X receptors, and metabotropic P2Y receptors (Lohman & Isakson 2014,
Singh, Boyer, Der & Zohn 2010). Purinergic receptors are broadly distributed in neurons
and glial cells, and these receptors have a high binding affinity to ATP and ADP
nucleotides.
11

Seven subtypes of the ionotropic P2X receptor family and eight metabotropic P2Y
receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14) occur. Three
P2Y receptors are preferentially activated by ADP: P2Y1, P2Y12 and P2Y13 (Espelt et
al. 2013). P2Y2 is preferentially activated by UTP or ATP (Solfoff, Avraham, Avraham
& Cantley 1998). Overall, the metabotropic P2Y receptors have been shown to couple to
Gq, Gs, or Gi and modulate intracellular inositol triphosphate (IP3), calcium, and cyclic
AMP (cAMP) levels (Lohman & Isakson 2014). Recent studies which examined
metabotropic P2Y receptor roles during osmotic challenge in retinal glia (Müller) cells
found activation of the purinergic receptor signaling cascade mediated swelling in this
cell type (Vogler et al. 2016).

ATP role in RVD
ATP stimulation of purinergic signaling through the P2Y2 receptors (P2Y2R) may play a
role in modulating RVD response during cell swelling (Dezaki, Tsumura, Maeno &
Okada 2000). P2Y2 receptors have been shown to be ubiquitously expressed on the
plasma membrane in rodent fibroblasts (Homolya et al. 1999), in prostate cancer cells (Li
et al. 2013) and cortical astroglia (Fischer et al. 2009) during homeostatic and
osmotically challenged conditions (Lohman & Isakson 2014, Singh, Boyer, Der & Zohn
2010). And for astrocytes, specifically, P2Y receptors are expressed on the cell plasma
membrane in vivo and in vitro (Franke et al. 2001, Zhu & Kimelberg 2001). In hepatoma
cells, hypoosmotic swelling induced the release of endogenous ATP followed by the
activation of P2Y receptors and then an increase in volume-dependent current (Wang,
Mehta & Rose 1995). Furthermore, in the human epithelial cell line, Intestine407, ATP
12

release during osmotic swelling was shown to reach a concentration high enough to
stimulate P2Y purinergic receptors (Hazama et al. 1999). However, the application of
extracellular ATP under normal isoosmotic conditions has not been found to stimulate
volume sensitive chloride currents (Nilius, Sehrer & Droogmans 1994, Jackson &
Strange 1995, van der Wijk, De Jonge & Tilly 1999) suggesting purinergic activation of
ICl,swell requires osmotic swelling. In astrocyte cell cultures, exogenous ATP release
during hypoosmotic swelling activates ICl,swell through purinergic P2Y receptors (Darby et
al. 2003). The swelling-induced current was maximally activated at 1 mM extracellular
ATP concentration which is well above normal physiological conditions. Thus,
extracellular ATP’s effect on RVD is mediated, at least in part, by purinergic receptor
activation (Espelt et al. 2013).

ATP release pathways
Because purinergic receptors are activated by extracellular nucleotides, drugs which
cause hydrolysis of extracellular ATP, inhibit the purinergic receptor, or limit ATP
release may be tools for studying purinergic receptor activation during osmotic cell
swelling. Extracellular ATP and ADP concentrations can be reduced by various drugs
including apyrase, suramin, meclofenamate, and carbenoxolone. When added to the
intracellular or extracellular solutions in patch clamp studies, these drugs work by either
hydrolyzing ATP and ADP nucleotides to adenosine monophosphate (AMP) and
inorganic phosphate, competitive inhibition of purinergic receptors, or blocking
nucleotide release. Studies using Intestine407 cells have found extracellular application
of ATP enhanced RVD whereas the application of apyrase, an ATP hydrolyzing enzyme,
13

inhibited RVD (Dezaki, Tsumura, Maeno & Okada 2000). This behavior was also shown
by Espelt and colleagues in which they demonstrated that apyrase inhibits the swellinginduced chloride current while ATP and P2Y agonists stimulate this same current in Huh7 hepatoma cells (Espelt et al. 2013).
Suramin, a G-protein antagonist, was also shown to suppress RVD during cellular
swelling (Galietta et al. 1997). Suramin inhibits the Gα and Gβγ interface of the GPCR
in rat lung cell membranes (Chung & Kermode 2005). Suramin has also been shown to
inhibit volume-dependent taurine release in hippocampal neurons (Li & Olson 2004).
Suramin and its analogues are direct antagonists of heterotrimeric G-proteins and have
been found to act as quasi-competitive stimuli; that is, increasing the agonist
concentration overcomes suramin inhibition (Freissmuth, Waldhoer, Bofill-Cardona &
Nanoff 1999, Beindl et al. 1996). However, in human Intestine407 cells, suramin
treatment also interacts with the channel protein responsible for volume sensitive chloride
current unrelated to the drug’s role as a purinoreceptor blocker (Galietta et al. 1997; van
der Wijk, De Jonge & Tilly 1999). van der Wijk and colleagues’ research performed on
human Intestine407 cells treated with suramin and reactive blue suggested the channel
responsible for ICl,swell may share a homologous nucleotide-binding structure with
purinergic receptor proteins (van der Wijk, De Jonge & Tilly 1999). Similar observations
of the effects of extracellular ATP, suramin, and apyrase on RVD also have been found
in other cell types (Leal Denis et al. 2016, Dezaki, Tsumura, Maeno & Okada 2000,
Wang, Roman, Lidofsky & Fitz 1996).
Hemi-channels consisting of the gap junction proteins, connexins, have been suggested as
major ATP release channels (Locovei, Bao & Dahl 2006, Blum, Walsh & Dubyak 2009,
14

Thompson, Zhou & MacVicar 2006, Lohman & Isakson 2014). Connexins were first
described in 1970 as the principle protein making up a hemi-channel (Goodenough &
Revel 1970). Connexin monomers hexamerize to form half of a gap junction channel or a
hemi-channel on the plasma membrane. The hexamerized proteins dock with adjacent
cell hemi-channels to form a gap junction (Lohman & Isakson 2014). While gap
junctions act as a direct conduit between cells transferring intracellular ions and small
molecules such as ATP and aid electrical coupling between progenitor cells, neurons, and
glial cells, it has been proposed that certain isoforms of undocked connexin hemichannels may provide an efflux route for intracellular ATP (Lazarowski 2012).
Another family of channel forming proteins, pannexins, have been shown to oligomerize
and form similar hexameric channels to those formed by connexins. However, these
proteins do not form gap junction channels with adjacent cells and instead form single
membrane channels. Because of the structure similarity to hemi-channel proteins,
pannexin channels have also been implicated in extracellular ATP release (Sosinsky et al.
2011).
Several drugs have been shown to inhibit flux of ions and osmolytes through connexin
and pannexin hemi-channels (Tamura et al. 2011). Carbenoxolone is a well known
blocker of conductive ATP release through these gap junction protein hemi-channels.
Application of carbenoxolone during O2/Glucose deprivation studies using acutely
isolated hippocampal neuron preparations found carbenoxolone blocks hemi-channel
conductance in neurons (Thompson, Zhou & MacVicar 2006).
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Meclofenamate also suppresses ATP release via hemi-channels. Meclofenamate,
belonging to the fenamate class, are widely used as a non-steroidal anti-inflammatory
drug. Fenamates serve as cyclooxygenase inhibitors and also have been shown to play an
inhibitory role in ion channel activation including voltage gated potassium and calcium
channels (Li, Vapaatalo, Vaali & Paakkari 1998), ATP-sensitive potassium channels
(Grover et al. 1994), and gap junctions (Harks et al. 2001). Along with its role as a
connexin hemi-channel inhibitor, meclofenamate also has been suggested as a blocker of
ATP sensitive potassium channels (KATP) in cardiac cells (Grover et al. 1994). Patch
clamp studies using SKHep1 cells overexpressing connexin43 (Cx43) revealed that
meclofenamate also inhibited the Cx43-mediated intracellular communication (Harks et
al. 2001).

D. G-proteins and G-protein Coupled Receptors
Intracellular signaling mechanisms involve a molecule or stimulus which acts upon a
receptor molecule capable of perceiving the signal. This activation then leads to a second
messenger with further signaling cascades involved in normal cell processes. Many of
these signaling cascades in mammalian cells involve G-proteins, G-protein coupled
receptors (GPCRs), and effectors. GPCRs comprise the largest group of cell surface
receptors with over 1000 members, thus representing approximately 1% of the total
proteins encoded by the human genome (Schulte & Levy 2007). The common structural
model for the receptors consists of seven transmembrane regions (Lodish et al. 2000,
Tuteja 2009). GPCRs are activated by a variety of stimuli including growth factors,
neurotransmitters, hormones and chemoattractants. Activation of the receptor leads to a
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conformational change in the transmembrane α helices, and this conformational change
causes an exchange of GDP for GTP bound to the G-Protein α subunit. G-proteins are
transmembrane proteins coupled to cell surface receptors that act as secondary
messengers within the cell.
G-proteins consist of two main classes: heterotrimeric and GTPases. Heterotrimeric Gproteins consist of 3 subunits: alpha, beta, and gamma. This trimer is inactive when
reversibly bound to GDP. To mediate an intracellular event, the protein binds to GTP to
form an active complex. Hydrolysis of GTP by the alpha subunit alters the beta gamma
subunit and causes it to dissociate from the target protein. G-proteins then cycle between
the active GTP-bound state and the inactive GDP-bound state. Further signaling
transduction depends on the type of G-protein involved. Because trimeric G-proteins are
versatile, different receptor-hormone complexes can modulate activity for the same
effector protein.
The four main alpha subunits are: s, i, q, 12/13. The alpha s subunit has been found to
stimulate the adenylyl cyclase (AC) pathway while the activation of the alpha i subunit
has been shown to inhibit this same pathway. Activation of the alpha q subunit leads to
the stimulation of the PIP2 pathway. Lastly the alpha 12/13 subunit acts on the Rho
GTPase pathway. Rho-GTPase signaling pathways, independent of phosphorylation
events, have also been shown to regulate swelling induced chloride current in bovine
endothelial cells (Nilius et al. 1999).
G-protein subunits display an array of molecular diversity which has not been fully
understood (Beindl et al. 1996). In more recent years, GPCRs have been found to
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modulate potassium, calcium, and sodium voltage-gated ion channel activity in neurons
and other excitable cells (Abbracchio et al. 2006). And more recently, GPCR-regulated
ATP release has been shown to increase during hypoosmotic swelling in 1321N1
astrocytoma cells (Blum, Walsh & Dubyak 2009). Previous studies using native 1321N1
astrocytoma cells (which do not express functional purinergic receptors) found swelling
does not activate chloride currents and RVD does not occur following osmotic swelling
(Wenker & Olson 2008). Thus, a G-protein pathway initiated by purinergic signaling may
play a role in the signaling cascade involved with VRAC activation.
GTP is a purine nucleoside triphosphate well known for its involvement in DNA
synthesis but also through its role in G-protein activation and signal transduction. In
various cell types, application of GTPγS, a non-hydrolyzable GTP analog, has been
shown to increase chloride conductance (Doroshenko 1991, Tilly et al. 1991, Nilius et al.
1999), and this application of GTPγS has been shown to activate an outwardly rectifying
current independent of swelling (Doroshenko & Neher 1992, Estevez, Bond & Strange
2001). In calf pulmonary artery endothelial cells, VRAC is activated by GTPγS under
isoosmotic conditions (Voets et al. 1998). And in cervical cancer cells, extracellular
GTPγS application was found to facilitate the RVD process. Estevez and colleagues
found that ICl,swell stimulation did not require phosphorylation mechanisms and was
inhibited by GDPβS (another non-hydrolyzable GDP analog that competes with the GTP
binding site on the G-proteins) and Clostridium difficile toxin B (Estevez, Bond &
Strange 2001). Clostridium difficile toxin B (TcdB) is a potent cytotoxin which interacts
with small GTP binding proteins: Rho, Rac and Cdc42 (Voth & Ballard 2005).

18

Another toxin which affects GPCR responses is pertussis toxin. Pertussis toxin (PTX) is
an A-B exotoxin that inhibits G0 and Gi proteins via ADP-ribosylation. PTX acts by
preventing G-proteins from interacting with their GPCR by locking the α subunit in an
inactive state (Mangmool & Kurose 2011). Research has shown PTX may play a
therapeutic role in hypertension in rats (Kost, Herzer & Jackson 1999) and has been
shown to inhibit inwardly rectifying potassium channels in HEK293 cells (Leaney &
Tinker 2000). Researchers have also found that volume-activated taurine efflux mediated
by an anion channel in human cervical cancer cells HT-3 was inhibited by pertussis toxin
application (Chou, Shen, Chen & Huana 1997) suggesting pertussis toxin may be
blocking the VRAC channels involved in RVD. Thus, G-protein coupled receptors and
G-proteins may be implicated in the signaling cascade involved with VRAC activation
during cell swelling.
GPCR control of VRAC involves an increase in intracellular calcium ions, but it is
unclear whether intracellular calcium release is involved in RVD and whether these
changes involve purinergic signaling (McCarty & O'Neil 1992, Roe, Moore & Lidofsky
2001). However, this increased intracellular Ca2+ may be involved in PKC activation
through Ca2+ signaling cascades (Rudkouskaya, Chernoguz, Haskew-Layton & Mongin
2008). Protein kinase C (PKC) is a family of kinase enzymes that control protein function
by phosphorylation of the hydroxyl groups on serine and threonine amino acid residues.
PKC is widely expressed in all eukaryotic cells and has been shown to be involved in
EAA release (Rudkouskaya et al. 2008). However, there is controversy over the role of
PKC during ischemic injury. Some studies have shown up-regulated PKC-dependent
neuroprotective pathways while others have found a loss in PKC activity following acute
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ischemic injury. These conflicting reports may be tied to varying animal models used,
intensity of the ischemic onset, and the different PKC isozymes studied (Bright &
Mochly-Rosen 2005). PKC may play a role in VRAC activation and RVD response
following ischemic injury, but further studies are needed to determine this role.

E. Protease Activated Receptors
Another G-protein coupled receptor (GPCR) implicated in controlling cellular growth,
neuronal death, proliferation and inflammation, is the protease activated receptor (PAR)
family of proteins (Striggow et al. 2000). PARs are irreversibly activated by proteolytic
cleavage of the extracellular N terminus. The remaining amino terminus then functions as
a tethered ligand binding to the receptor which then irreversibly activates the PAR signal
transduction pathways. The PAR family of receptors consists of four known members:
PAR1, PAR2, PAR3, and PAR4. PAR1 was the first receptor discovered through its
interaction with thrombin. PAR1, PAR3, and PAR4 are activated by the coagulant
protease, thrombin, while PAR2 is activated by trypsin-like serine proteases such as
trypsin, tryptase, and upstream coagulation proteases, factors VIIa and Xa. PAR2 is not
activated by thrombin.

PAR downstream effects (G-protein pathways)
The serine protease, thrombin, is well known for its role in blood coagulation, however,
thrombin has also been implicated in synaptic plasticity and neurodegenerative disorders
such as Alzheimer’s dementia. Thrombin is generated from prothrombin during cell
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injury through either an extrinsic or intrinsic signaling cascade involving various blood
clotting proteins: tissue factor (TF) X, XI, XII, III, and V (Monroe, Hoffman & Roberts
2002). During acute brain injury, cells in the CNS are exposed to this serine protease.
Thrombin works by activating a phospholipase C (PLC) signaling cascade. In the
majority of cell types, PAR1 and PAR2 are often co-expressed on the cell membrane and
are involved in regulating downstream signaling pathways (Ubl, Vohringer & Reiser
1998, McCoy, Traynelis & Hepler 2010). Activation of the PAR1 receptor is capable of
activating G-protein families: Gi, G1 and G12/14 (Sorenson et al. 2003). Further research
has found that PAR1 activation from these G-protein pathways is involved in mediating
cell proliferation in rat primary astrocytes (Wang et al. 2002).

PAR actions on RVD and other functions
Studies using mouse brain slices have shown an upregulation of PAR1 during ischemic
conditions (Wang et al. 2012). It has been shown that thrombin has a neuroprotective
effect during cerebral ischemia when injected at a low dose, but at higher doses, thrombin
application has been shown to cause cell apoptosis and act more as a neurotoxin
(Striggow et al. 2000, Donovan & Cunningham 1998, Xi, Reiser & Keep 2003). PAR1
upregulation during acute ischemia also has been associated with apoptosis in cultured
neurons and astrocytes and with glial cell proliferation. This thrombin-induced neuronal
cell death was associated with activation of RhoA. Activation of RhoA was also found to
be inhibited by tyrosine kinase inhibitors suggesting tyrosine kinase is required upstream
in the signaling cascade (Donovan, Pike, Cotman & Cunningham 1997, Donovan &
Cunningham 1998).
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PAR has been found to increase ATP release during cell swelling. Thrombin activation of
PAR receptors in 1321N astrocytoma cells causes ATP release under isoosmotic
conditions and this release is enhanced during hypoosmotic stress (Joseph, Buchakjian &
Dubyak 2003). Blum and colleagues found that the osmotically enhanced PAR1dependent ATP release in the 1321N1 cell type was completely eliminated under
hypertonic conditions (Blum, Walsh & Dubyak 2009). This suggests that ATP release
following PAR receptor activation is osmotically dependent. PAR1 receptors also have
been shown to reduce the threshold osmolarity for taurine release in 1321N1 astrocytoma
cells (Cheema, Ward & Fischer 2005).

F. Summary of Background Literature
Volume regulated anion channels (VRAC) play an important role in regulatory volume
decrease (RVD) following hypoosmotic stress. VRAC has been implicated as the channel
responsible for ICl,swell (Voss et al. 2014). Because chloride is the most abundant anion in
the cell, this channel is a major contributor to volume regulation. While the channel is
characterized electrophysiologically, pharmacologically, and more recently, structurally,
not much is known regarding channel activation, pore formation, membrane recruitment,
and the upstream regulators involved. In this study, I am specifically concerned with
VRAC activation in brain cells and the possible upstream regulators of VRAC gating and
activation such as G-proteins, ATP, and the protease activated receptors.
Extracellular ATP has been suggested to regulate VRAC during hypoosmotic exposure in
primary rat astrocytes (Mongin & Kimelberg 2002). Other research has shown a
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thrombin-enhanced ATP release in 1321N1 cells in vitro that is sensitive to osmotic
conditions (Blum, Walsh & Dubyak 2009); however, extracellular ATP has not been
found to stimulate VRAC under isotonic conditions (Nilius, Sehrer & Droogmans 1994,
Jackson & Strange 1995). Thus, I will investigate the roles of GPCR signaling, purinergic
signaling through P2Y2 receptors, PAR1 activation, and extracellular ATP-dependent
pathways on ICl,swell during RVD.
As shown in Figure 1, I propose that PAR1 activation via thrombin and/or P2Y2 receptor
activation by exogenous ATP will activate VRAC. I propose that inhibition of these
pathways will inhibit swelling-induced chloride currents through this channel in this
tumor cell type.

Figure 1: Schematic view of proposed upstream regulators of VRAC during cell
swelling
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II. Specific Aims
Specific Aim I
Identify and characterize VRAC in a P2Y2R-transfected astrocytoma cell line. VRAC
will be pharmacologically and electrophysiologically identified.
Specific Aim II
Determine if VRAC can be activated under isoosmotic conditions using ATP and other
G-protein coupled receptor activators.
Specific Aim III
Determine if VRAC activation during hypoosmotic exposure is G-protein coupled. This
will be addressed pharmacologically using exogenous ATP and thrombin application, Gprotein activators and G-protein inhibitors and through the addition of pertussis toxin
intracellularly.
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III. Materials and Methods
A. Abbreviations
ADP = adenosine 5’-diphosphate, ATP = adenosine 5’-triphosphate, ClC-X = chloride
channel family, CNS = central nervous system, CsCl = cesium chloride, DCPIB = 4-[(2Butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-ox o1H-inden-5-yl)oxy]butanoic acid,
DIDS = 4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid, DMEM = Dulbecco's
modified Eagles medium, DMSO = dimethyl sulfoxide, EGTA = ethylene glycol
tetraacetic acid, FBS = fetal bovine serum, GDP = guanosine 5’-diphosphate, GPCR =
G-protein couple receptor, GTP = guanosine 5’-triphosphate, HEPES = 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, NKCC = Na+/K+/2Cl- symporter, NPPB
= 5-nitro-2-(3-phenylpropyl-amino) benzoic acid, PAR = protease activated receptor,
PBS = phosphate buffer solution, PKC = protein kinase C, PTX = pertussis toxin, RVD
= regulatory volume decrease, RVI = regulatory volume increase, SITS = 4-Acetamido4'-isothiocyanatostilbene-2,2'-disulphonic acid, VRAC = volume regulated anion
channel.

B. Materials
The following materials were used to perform the experiments in this thesis: low-glucose
DMEM, thrombin from bovine plasma, geneticin (G418), DMSO, HEPES, EGTA, Na2-
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ATP, pertussis toxin lyophilized powder, meclofenamate sodium, carbenoxolone
disodium salt, and suramin sodium salt were purchased from Sigma-Aldrich (St. Louis,
MO), Penicillin/streptomycin, trypsin 0.25%, and FBS were purchased from Invitrogen
(Carlsbad, CA), and DCPIB purchased from Tocris Biosciences (Ellisville, MO)
Other chemicals used were CsCl and CsOH purchased from Sigma-Aldrich (St. Louis,
MO), CaCl2 and dextrose purchased from J.T. Baker Chemical Co. (Phillipsburg, NJ),
and MgCl2 purchased from MCB Reagents (Cincinnati, OH).

C. Cell Culture
The cells used in the experiments are transgenic clones of 1321N1 human astrocytoma
cells which express the human P2Y2 receptor. These cells had been stably transfected
with the human P2Y2 receptor subtype (P2Y2 cells) and simultaneously transfected with
resistance to geneticin (G418), an aminoglycoside antibiotic similar in structure to
gentamicin that blocks ribosomal protein synthesis in prokaryotic and eukaryotic cell
lines. The cells were a gift by Natalia Chorna, Ph.D. (University of Puerto Rico, San
Juan, Puerto Rico) and were shipped in low-glucose Dulbecco’s modified Eagles medium
(DMEM). They were replated upon arrival in growth media containing low-glucose
DMEM, 5% FBS, 1% penicillin/streptomycin, and 0.5 g/L G418. At 90% confluency,
cells were removed and resuspended in similar growth media but containing 10% DMSO
and 20% FBS before being cryogenically frozen at 77ºK in 1 mL aliquots for stable longterm storage.
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After rapidly thawing, cells were cultured in plastic petri dishes with growth media and
incubated in a humidified atmosphere containing 5% CO2 and 95% air at 37ºC. Growth
media was replaced every 3-4 days and once the cells reached 90% confluency, they were
replated. Replating of cells consists of treating the cells with 0.25% trypsin solution for 510 minutes to loosen the cells from the surface. The resulting cell suspension then was
centrifuged for 5 minutes at 300 × g. Then the trypsin solution was removed through
aspiration and the remaining pellet resuspended in fresh growth medium. A fraction of
the suspension was then replated with additional growth media. Cells used for patch
clamp experiments were plated two days prior to the electrophysiological recordings on
sterilized 12 mm coverslips placed in the petri dishes.

D. Electrophysiological Recording
Coverslips with attached cells were placed on the stage of a Nikon TMS-F inverted phase
contrast microscope (Tokyo, Japan) containing a single-coverslip chamber (Warner Dual
Heater Controller TC-344, Hamden, CT). Coverslips were perfused with a phosphate
buffer solution (PBS) using a Cell-Micro Controls perfusion system (Norfolk, VA) at a
rate of 2-3 mL/min. The PBS solution contained (in mM): NaCl (147), KH2PO4 (0.5),
Na2HPO4 (3.2), CaCl2 (1.0), MgCl2 (0.5), dextrose (5.0), KCl (2.7) and pH was adjusted
to 7.3 using NaOH. The final osmolarity of the solution was adjusted to 290 mOsm using
small volumes of 3 M NaCl and confirmed with a Wescor vapor pressure osmometer
(Logan, UT). The chamber temperature was measured with a thermocouple and held at
35ºC using integral heating elements. Excess fluid from the perfusion system was
removed via a vacuum system to maintain a constant fluid level.
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Patch pipettes were pulled in two stages from thin-walled glass capillary tubes (World
Precision Instruments Inc., Sarasota, FL) using a Narishige PP-83 puller (East Meadow,
NY). The electrode was filled with a CsCl solution containing (in mM): CsCl (100),
CaCl2 (1.0), MgCl2 (1.0), EGTA (10), HEPES (10), Na2ATP (5.0), glucose (5.5), and
approximately 100 mM of sucrose with a final osmolarity adjusted to 290 mOsm using
sucrose and pH was adjusted to 7.3 using CsOH. When filled with a CsCl solution, patch
pipettes had a resistance of 3-5 MΩ.
Whole cell recordings were initiated while PBS perfused the recording chamber. The
electrode was lowered into the bath solution and manipulated so that the tip was adjacent
to the cell membrane. While the pipette tip was in this solution, the pipette offset was set
to 0 mV and the pipette resistance measured at a holding membrane potential of 0 mV
using an Axopatch 200A amplifier (Union City, CA) controlled with Clampex 2.0
software (Union City, CA). The electrode was then advanced toward the cell surface.
Upon contact with the cell, light suction was applied to the electrode solution to draw the
cell membrane into the pipette tip. Once the pipette resistance was greater than one
gigaohm, more suction was applied to break the cell membrane that had been drawn into
the pipette. In all experiments, cell capacitance then was measured in Clampex 8.2
software (Union City, CA) while holding the cell in PBS solution. Capacitance was used
to normalize the measured whole cell currents to current density units of nA/pF.
Within two minutes of obtaining a stable whole cell recording, the bath perfusion solution
was switched to isoosmotic CsCl solution consisting of (in mM): CsCl (100), CaCl2 (1),
MgCl2 (0.5), HEPES (10), sucrose (90), glucose (5.5). The membrane potential for all
experiments was held in voltage clamp mode at 0 mV using an Axopatch 200A Axon
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Instruments amplifier (Union City, CA). A series of 100 msec voltage command pulses
was applied to the cell membrane every 30 sec in a stepwise fashion from -100 mV to
+120 mV or from -90 mV and +130 mV in increments of 20 mV. After 3-5 min of
perfusion in isoosmotic CsCl solution, the perfusion solution was changed to a
hypoosmotic CsCl solution with an osmolality of either 250 mOsm or 200 mOsm. These
hypoosmotic solutions were identical to isoosmotic CsCl solutions except that the
concentration of sucrose was lowered to achieve the desired solution osmolality.
In some experiments, DCPIB, ATP, thrombin, carbenoxolone, meclofenamate, or
suramin were added to the CsCl perfusion solution. And in other experiments, pertussis
toxin was added to the CsCl pipette solution

E. Data Analysis and Calculations
Whole cell currents were recorded using Axon Instruments Clampex 2.0 software (Union
City, CA). Current measurements collected between 5 msec and 8 msec after the start of
each voltage step were averaged using Axon Instruments Clampfit 8.2 software (Union
City, CA) and then transferred to Microsoft Excel for analysis. These data points were
chosen to obtain the maximum current prior to inactivation of VRAC which appears after
the first 10 msec of the voltage pulse. Data for cells in isoosmotic CsCl solution were
taken approximately 3 minutes after the start of the perfusion in this solution and data for
the hypoosmotic treatments was taken at 5-6 minutes after the solution was changed. Cell
current density was expressed in units of nA/pF determined by dividing the membrane
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current (I) by the total cell capacitance (C). Current density voltage plots were
constructed for the data and standard error bars were calculated from the data sets.

F. Data Analysis
Current density measurements measured at +120 mV or +130 mV were used for analysis.
Data were analyzed by ANOVA or Students t-test for paired or unpaired samples with
significance indicated for p<0.05 for a two-tailed distribution. All values are reported as
the mean ± SEM. Clampfit 8.2 (Axon Instruments, Union City, CA) software was used
for this statistical analysis.
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IV. Results
A. P2Y2 transfected astrocytoma cells exhibit swelling-induced chloride conductance
The electrophysiological response to hypoosmotic exposure was evaluated by the voltage
clamp technique. Under whole-cell voltage clamp conditions with the CsCl pipette
solution and the cells perfused with isoosmotic (290 mOsm) PBS solution, cell
capacitance was measured. Capacitance is a good approximation tool for biological
membranes (Alvarez & Latorre 1978) and is used to normalize cell membrane surface
area/size. The astrocytoma cells displayed capacitances between 20 and 80 pF.
Currents observed during isoosmotic (290 mOsm CsCl) perfusion were small in
magnitude, slightly outwardly rectifying, and displayed little to no time dependent
inactivation (Figure 2). The cells demonstrated an increase in current amplitude within 35 minutes of hypoosmotic exposure. This hypoosmotically activated current showed time
inactivation at depolarized potentials. The swelling-induced current was also found to be
present when the cell was perfused with 250 mOsm CsCl as shown in Figure 2. The
current activated during the 250 mOsm CsCl perfusion showed slightly less maximum
activation at positive potentials suggesting the magnitude of the current is related to the
degree of cellular swelling.
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Figure 2: VRAC is present in 1321N1 astrocytoma cells transfected with P2Y2
receptors. A) Cell currents recorded while the cell was perfused with 290 mOsm CsCl
solution, B) perfused with 250 mOsm CsCl solution, and C) perfused with 200 mOsm
CsCl. Current density was calculated using the capacitance of each cell and an average of
the cell recordings was used to create the I-V chart. D) Current-voltage relationships for
isoosmotic 290 mOsm exposure, hypoosmotic 200 mOsm exposure and hypoosmotic 250
mOsm exposure. E) Swelling-activated current for 200 mOsm CsCl exposure (n=11) and
250 mOsm CsCl exposure (n=4). The (*) indicates swelling-activated current in 200
mOsm is statistically larger than the current in 250 mOsm by two-way ANOVA.
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B. The current activated by hypoosmotic exposure is DCPIB-sensitive
To determine if this swelling-activated current is associated with VRAC, DCPIB (100
µM) was added to the bath solution for 2-3 minutes prior to changing from isoosmotic to
hypoosmotic (200 mOsm) CsCl solution and was present throughout the isoosmotic and
hypoosmotic exposure. Whole-cell recordings show the current normally activated during
hypoosmotic treatment was greatly diminished when DCPIB is present in the bath
solution (Figure 3) suggesting that DCPIB inhibits the channel or upstream regulators
involved with channel activation.

C. VRAC is inhibited by G-protein inhibitors
To determine if G-proteins or G-protein coupled receptors are involved in VRAC
signaling and/or activation, 100 μM suramin, a G-protein antagonist, was added to the
bath solution during isoosmotic and hypoosmotic treatments. Figure 3 shows that adding
suramin has no significant effect during 290 mOsm CsCl treatments. However, VRAC
was significantly inhibited when suramin was present during perfusion with the 200
mOsm solution (p=0.0024).
Addition of 1 µg/mL pertussis toxin to the patch solution gave similar results to those
observed with extracellular suramin treatments. Pertussis toxin had no effect during
isoosmotic CsCl perfusion, but significantly reduced the VRAC current during
hypoosmotic exposure.
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D. Thrombin enhances chloride conductance during cell swelling
Thrombin is a serine protease found to activate three of the known G-protein coupled
protease activated receptors (PAR): PAR1, PAR3, and PAR4. To determine if PAR can
enhance the RVD response of VRAC, 5 U/mL thrombin was added to isoosmotic and
hypoosmotic (200 mOsm) perfusion solutions (Figure 3). Thrombin added during
isoosmotic perfusion did show a significant effect on membrane current (p=0.0105).
Additionally, with thrombin present during hypoosmotic exposure, a significant increase
in the magnitude of the hypoosmotic current was also observed (p=0.0005).
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Figure 3: Drugs that act on VRAC conductance. For control recordings, current was
measured while cells were perfused in isoosmotic 290 mOsm CsCl solution and
hypoosmotic 200 mOsm CsCl bath solution without added drug (n=11). Current density
was calculated using the capacitance of each cell and an average was taken at +120 mV
holding potential. When DCPIB (100 µM, n=6), suramin (100 µM, n=5), or thrombin (5
U/mL, n=5) was used, the drug was present in both the isoosmotic and hypoosmotic
perfusion solutions. Pertussis toxin (1 µg/mL, n=7) was added to the CsCl pipette
solution during both isoosmotic and hypoosmotic exposure. Error bars show the standard
error of the mean for each set of data. The (*) indicates significance (α<0.05) in
comparison to control recordings.
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E. Endogenous ATP does not affect VRAC activation
To determine the effect of exogenously applied ATP on the swelling-activated current,
100 µM ATP was added to the isoosmotic CsCl perfusion solution and was present at the
same concentration in the hypoosmotic (200 mOsm) CsCl perfusion solution. Figure 4
shows 100 µM exogenous ATP does not significantly enhance the conductance during
perfusion with 290 mOsm CsCl solution. Similarly, there was no significant effect on the
swelling-induced current in hypoosmotic 200 mOsm CsCl perfusion solution.
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Figure 4: The effect of exogenous ATP on VRAC. For isoosmotic and hypoosmotic
recordings, current was measured while cells were perfused in 290 mOsm CsCl solution
and 200 mOsm CsCl perfusion solution, respectively. Current density was calculated
using the capacitance measured for each cell and the average current measured at +120
mV. For control recordings, currents were measured in the absence of exogenous ATP
Data from the ATP group are from cells exposed to 290 mOsm CsCl (isoosmotic) and
200 mOsm CsCl (hypoosmotic) solutions in the presence of 100 µM ATP Values are the
mean for 11 cells in control and 9 cells in ATP groups. Error bars show the standard
error of the mean for each set of data.
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F. Limiting ATP release pathways had no effect on VRAC conductance
I tested if reducing the extracellular ATP concentration or limiting cellular ATP release
pathways that are activated by cell swelling would affect VRAC activation.
Apyrase, an ATP hydrolyzing enzyme, was added to the bath solutions and current
density was measured at +120 mV. Figure 5A shows 5 U/mL apyrase added to the 290
mOsm solution had no effect on whole cell current density. However, apyrase reduced
the hypoosmotic current when present in the 200 mOsm bath solutions (p=0.0314).
Meclofenamate and carbenoxolone inhibit conductance of gap junction hemi-channels
and by doing so reduce ATP release during cell swelling (Harks et al. 2001, Thompson,
Zhou & MacVicar 2006). When 100 μM meclofenamate was present during hypoosmotic
exposure, there was no significant effect on the swelling-activated current. However,
when 100 μM carbenoxolone was added to the 200 mOsm solution, I saw a significant
inhibitory effect on this current (p=0.0001).
Finally, I tested to see if the current inhibition during hypoosmotic perfusion caused by
carbenoxolone could be reversed by adding ATP or thrombin to the perfusion solution.
For these experiments, the voltage step protocol was performed with 20 mV steps
between -90 mV to +130 mV. Data were taken at +130 mV. Previous studies showed
addition of thrombin (Figure 3) did increase chloride conductance during isoosmotic
CsCl treatments but added ATP (Figure 4) did not affect VRAC during isoosmotic
exposure. ATP or thrombin was added to the hypoosmotic CsCl bath solution containing
100 μM carbenoxolone (Figure 5B).

I found no recovery of the swelling-activated

current when ATP was present in the 200 mOsm solution containing carbenoxolone.
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However, adding 5 U/mL thrombin to the hypooosmotic solution containing
carbenoxolone resulted in a partial recovery of the hypoosmotic current (p=0.0109).
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Figure 5: The effect of limiting hemi-channel ATP release on VRAC activation.
Current was measured while cells were perfused in isoosmotic (290 mOsm) CsCl
solution and hypoosmotic (200 mOsm) CsCl bath solution. For control recordings
(n=11), current was measured while cells were perfused in isoosmotic 290 mOsm CsCl
solution and hypoosmotic 200 mOsm CsCl bath solution without added drug. Current
density was calculated using the capacitance of each cell and an average was taken at
+130 mV readings. (A) 5 U/mL apyrase was added to the 200 mOsm CsCl bath solution
(n=5). 100 µM carbenoxolone was added to the 200 mOsm CsCl bath solution (n=6). 100
µM meclofenamate was added to the 200 mOsm CsCl bath solution (n=3). (B) 100 µM
carbenoxolone was added to the 290 mOsm and 200 mOSm bath solutions. 100 µM
carbenoxolone and 100 µM ATP was added to the 200 mOsm CsCl bath solution (n=5).
100 µM carbenoxolone and 5 U/mL thrombin was added to the 200 mOsm bath solution
(n=4). Data show mean values for each experiment and error bars display SEM for each
set of data. The (*) in A indicates significance (α<0.05) in comparison to the mean value
measured in the same osmolality without drug. The (*) in B indicates significance
(α<0.05) in comparison to the mean value measured in the same osmolality with
carbenoxolone inhibition.
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V. Discussion
A. Summary of experimental approach
For decades, research has examined the channel responsible for the swelling-induced
chloride current, ICl,swell, because this channel appears to play an important role in
regulating cell volume following cellular swelling (Okada et al. 2001, Nilius &
Droogmans 2003). The identity of this channel, termed the volume regulated anion
channel (VRAC), has been characterized electrophysiologically, pharmacologically, and
structurally. VRAC conductance consists of an outwardly-rectifying anion-selective
current at depolarized potentials (Blum, Walsh & Dubyak 2009). This current is
predominantly present in swollen cells and develops within the first few minutes
following hypotonic challenge. Inactivation of the current occurs at hyperpolarized
potentials and can vary between cell types (Nilius, Sehrer & Droogmans 1994). LRRC8A
proteins form an oligomer, SWELL1, during osmotic challenges. These complexes are
sufficient to form anion channels sensitive to osmotic stress (Syeda et al. 2016).
Topology of this protein complex suggests the leucine-rich pore forming structure is
imbedded inside the plasma membrane (Qiu et al. 2014). However, channel gating and
pore formation is still not understood.
I examined VRAC activation in P2Y2 stably-transfected 1321N1 astrocytoma cells using
the voltage clamp procedure. To isolate chloride conductances through the plasma
membrane, cesium chloride (CsCl) was used in the extracellular bath solution and
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intracellular patch solution. Assuming there is no permeability pathway for cesium ions,
by using CsCl solute in the intracellular and extracellular solutions, I eliminated K+
currents and was thus able to isolate negatively charged chloride ion movement across
the plasma membrane using whole-cell patch clamp electrophysiological studies. The
role of the P2Y2 receptor and downstream G-protein signaling was investigated
pharmacologically.

B. Identification of VRAC in 1321N1 cells
VRAC shows an outwardly rectifying chloride conductance during cellular swelling,
displays time-dependent inactivation at depolarizing membrane potentials, and is blocked
by DCPIB (Decher et al. 2001, Walsh & Dubyak 2009). In this study, P2Y2 transfected
1321N1 cells displayed such an outwardly rectifying chloride current with timedependent inactivation at depolarized potentials during hypoosmotic exposure. This
chloride current was not active under isoosmotic conditions. Additionally, a smaller
chloride current similar in time and voltage dependence was observed when cells were
treated with 250 mOsm hypoosmotic CsCl solution suggesting the magnitude of ICl,swell
activation is related to the degree of cell swelling. Finally, this current was significantly
inhibited in the presence of DCPIB. Thus, I conclude VRAC is present in these tumor
cells and VRAC is the channel responsible for ICl,swell during cell swelling of the 1321N1
cells.
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C. GPCRs are necessary for VRAC activation
P2Y2R purinergic signaling via ATP stimulation may play a role in modulating the RVD
response associated with cell swelling (Dezaki, Tsumura, Maeno & Okada 2000).
Previous studies using 1321N1 astrocytoma cells found the native cell type possesses no
function purinergic receptors, does not activate chloride currents, and does not show a
RVD (Wenker & Olson 2009). I used 1321N1 stably transfected with the human P2Y2
receptor in these experiments to determine the role purinergic signaling through this Gprotein couple receptor may play in VRAC activation. These receptors have been shown
to enhance volume-activated currents following ATP release in other cell types (Wang,
Mehta & Rose 1995). This volume-activated current is not observed in isoosmotic
conditions (Jackson & Strange 1995). To determine if G-protein coupled receptors are
involved in VRAC activation in these P2Y2 transfected cells, I used the G-protein
inhibitors pertussis toxin (PTX) and suramin. Pertussis toxin is an A-B exotoxin that
inhibits G0 and Gi proteins via ADP-ribosylation. PTX acts by preventing G-proteins
from interacting with their GPCR by locking the α subunit in an inactive state
(Mangmool & Kurose 2011). When PTX was added to the pipette solution during
hypoosmotic exposure VRAC activation was significantly reduced
Similarly, when suramin, a P2Y receptor antagonist, was added to the bath solution, a
significant inhibition of the swelling-induced chloride current was observed. These
results suggest GPCR is necessary for VRAC activation.
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D. PAR activates an osmotically-sensitive chloride current
Previous studies found PAR activation in 1321N1 cells resulted in an increase in ATP
release during isoosmotic and hypoosmotic conditions (Joseph, Buchakjian & Dubyak
2003). In bovine artery endothelial cells, activation of PAR led to an increase in ICl,swell
(Manolopoulos, Prenen, Droogmans & Nilius 1997). I found the application of 5 U/mL
thrombin enhanced the current activation during cell swelling along with the current
activation during isoosmotic CsCl exposure in 1321N1 astrocytoma cells. These results
suggest PAR may activate an osmotically-sensitive chloride current, but this chloride
efflux is not through the volume regulated anion channel.

E. ATP release through hemi-channels is not necessary for VRAC activation
Exogenously applied ATP enhances swelling-induced chloride current during
hypoosmotic exposure of primary cultured astrocytes (Darby et al. 2003). However, since
swelling itself may cause ATP release it is not clear whether ATP is necessary for
channel activation. Therefore, I examined the effect of additional extracellular ATP on
VRAC activation as well as the effect of removing ATP from the extracellular fluid or
inhibiting ATP release pathways. Apyrase hydrolyzes ATP to ADP and AMP species
which are less powerful agonists of the P2Y2 receptor while carbenoxolone and
meclofenamate block ATP release through gap junction hemi-channels. When 100 μM
ATP was added to the cesium chloride bath solution there was no significant change in
VRAC activity during isoosmotic or hypoosmotic exposure. Thus, extracellular ATP is
not sufficient to activate this channel. Research has suggested ATP release during cell
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swelling is required for ICl,swell (Darby et al. 2003). To limit the extracellular ATP
concentration, I added 5 U/mL apyrase, to the bath solution. This resulted in a small
reduction in VRAC activation during hypoosmotic exposure which was significant,
findings similar to those seen in Intestine407 cells where apyrase inhibited RVD (Dezaki,
Tsumura, Maeno & Okada 2000). The results from these experiments suggest
extracellular ATP is involved in activating VRAC but only in cells swollen by
hypoosmotic exposure.
Meclofenamate, a connexin hemi-channel inhibitor, had no significant effect on VRAC
activity during hypoosmotic exposure, however, carbenoxolone, a selective gap junction
blocker did demonstrate a significant inhibitory effect on VRAC conductance. These
results are similar to those found by Thompson, Zhou and MacVicar in hippocampal
neurons (Thompson, Zhou & MacVicar 2006). However, subsequent to performing these
experiments other investigators reported that carbenoxolone directly inhibits VRAC
(Benfenati et al. 2009). Thus, I cannot conclude that carbenoxolone is blocking VRAC
activation by reducing the release of intracellular ATP via gap junction hemi channels.
ATP and thrombin also were added to hypoosmotic perfusion solutions containing
carbenoxolone. Adding ATP to the bath solution had no significant effect on VRAC
activation suggesting that 100 μM extracellular ATP cannot reverse the inhibition due to
carbenoxolone.

However adding 5 U/mL of thrombin to cells perfused with

carbenoxolone did show an increased chloride current measured in hypoosmotic
conditions when compared to cells perfused with carbenoxolone inhibition. Because
carbenoxolone has been found to block VRAC, this increase by thrombin in the chloride
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current measured in hypoosmotic conditions is through a separate chloride conductance
pathway from VRAC.

F. Conclusion
Previous research has shown chloride current is increased during hypoosmotic exposure
(Zhang & Jacob 1997). VRAC is the channel which causes this increased chloride
current, ICl,swell. However, the mechanisms of activation, channel gating, and plasma
membrane insertion of channel proteins are not entirely understood. Using voltage clamp
procedures during hypoosmotic exposure, I isolated the chloride current associated with
VRAC in P2Y2 transfected 1321N1 cells.
Since decreasing the extracellular ATP concentration reduces the magnitude of VRAC
activation, I conclude that purinergic signaling plays a role in activating this channel.
However, exogenous ATP does not activate VRAC in isoosmotic conditions or enhance
the chloride current during hypoosmotic exposure. Adding carbenoxolone to the bath
solution did show an inhibitory effect on VRAC in the tumor cells which agrees with the
findings by Darby et al. (2003); however, it is unclear if carbenoxolone acts on VRAC
directly or affects VRAC by limiting ATP release through hemi-channels. Future
experiments may be considered to determine if higher concentrations of ATP have any
effect on channel activation in this cell type.
The enhancement of hypoosmotic activated anion current by thrombin suggests PAR may
affect osmotically-sensitive chloride current but this current is not through VRAC. Thus,
PAR may activate a separate chloride conductance pathway during cell swelling.
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I have found that GPCR is involved in channel activation. Inhibition of P2Y2R or the Gprotein signaling pathway during hypoosmotic exposure was found to inhibit the anion
current associated with VRAC. However it is unclear what role GPCR is involved in
channel activation, gating, and/or pore formation.
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